Welcome to LookChem.com Sign In|Join Free
  • or
Ethyl 2-[(3-bromophenyl)amino]acetate is a chemical compound characterized by the molecular formula C10H12BrNO2. It is a white to pale yellow solid at room temperature, exhibiting solubility in organic solvents. ethyl 2-[(3-bromophenyl)amino]acetate is widely utilized in the synthesis of pharmaceuticals and agrochemicals, and also serves as an intermediate in the production of dyes, pigments, and other organic compounds. Classified as a potentially hazardous chemical, it necessitates careful handling and adherence to proper safety protocols.

2521-91-7

Post Buying Request

2521-91-7 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

2521-91-7 Usage

Uses

Used in Pharmaceutical Synthesis:
Ethyl 2-[(3-bromophenyl)amino]acetate is employed as a key intermediate in the synthesis of various pharmaceuticals. Its unique chemical structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Production:
ethyl 2-[(3-bromophenyl)amino]acetate is also utilized in the production of agrochemicals, contributing to the development of effective pesticides and other agricultural products that enhance crop protection and yield.
Used in Dye and Pigment Manufacturing:
Ethyl 2-[(3-bromophenyl)amino]acetate serves as an intermediate in the manufacturing process of dyes and pigments, enabling the creation of a diverse range of colorants for various industries, including textiles, plastics, and printing inks.
Used in Organic Compound Synthesis:
As a versatile intermediate, ethyl 2-[(3-bromophenyl)amino]acetate is used in the synthesis of other organic compounds, expanding its applications across different chemical and industrial sectors.
Used in Chemical Research:
Due to its unique properties and reactivity, ethyl 2-[(3-bromophenyl)amino]acetate is also employed in chemical research for the exploration of new reactions and the development of innovative synthetic methodologies.

Check Digit Verification of cas no

The CAS Registry Mumber 2521-91-7 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,5,2 and 1 respectively; the second part has 2 digits, 9 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 2521-91:
(6*2)+(5*5)+(4*2)+(3*1)+(2*9)+(1*1)=67
67 % 10 = 7
So 2521-91-7 is a valid CAS Registry Number.
InChI:InChI=1/C10H12BrNO2/c1-2-14-10(13)7-12-9-5-3-4-8(11)6-9/h3-6,12H,2,7H2,1H3

2521-91-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name ethyl 2-(3-bromoanilino)acetate

1.2 Other means of identification

Product number -
Other names ethyl N-(3-bromophenyl)glycinate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:2521-91-7 SDS

2521-91-7Relevant academic research and scientific papers

Visible-Light-Induced Oxidative α-Alkylation of Glycine Derivatives with Ethers under Metal-Free Conditions

Song, Yang,Zhang, Hao,Guo, Jiabao,Shao, Yifei,Ding, Yuzhou,Zhu, Li,Yao, Xiaoquan

, p. 5914 - 5921 (2021/11/22)

In this work, a visible-light-induced oxidative α-alkylation of glycine derivatives with ethers has been developed in the presence of catalytic Eosin Y. Under the blue light of a 3 W LED, a range of α-etherized glycine derivatives, including α-amino esters, α-amino ketones and α-amino amides, were achieved with good to excellent yields and functional group tolerance with tert-butyl hydroperoxide (TBHP) as oxidant at ambient temperature. The operationally easy procedure provides an economical, metal-free, and mild alternative for the synthesis of the α-etherized glycine derivatives.

Arylamino containing hydroxamic acids as potent urease inhibitors for the treatment of Helicobacter pylori infection

Liu, Qi,Shi, Wei-Kang,Ren, Shen-Zhen,Ni, Wei-Wei,Li, Wei-Yi,Chen, Hui-Min,Liu, Pei,Yuan, Jing,He, Xiao-Su,Liu, Jia-Jia,Cao, Peng,Yang, Pu-Zhen,Xiao, Zhu-Ping,Zhu, Hai-Liang

, p. 126 - 136 (2018/07/13)

A novel series of aniline-containing hydroxamic acids were designed, synthesized and evaluated as anti-virulence agents for the treatment of gastritis and gastric ulcer caused by Helicobacter pylori. In vitro enzyme-based screen together with in vivo assays and structure?activity relationship (SAR) studies led to the discovery of three potent urease inhibitors 3-(3,5-dichlorophenylamino)–N-hydroxypropanamide (3a), 3-(2-chlorophenylamino)–N-hydroxypropanamide (3d) and 3-(2,4-dichlorophenylamino)–N-hydroxypropanamide (3n). Compounds 3a, 3d and 3n showed excellent urease inhibition with IC50 values 0.043 ± 0.005, 0.055 ± 0.008 and 0.018 ± 0.002 μM, and significantly depressed gastritis developing at the dose of 32 mg/kg b. i.d with eradication rates of H. pylori reaching 92.3, 84.6 and 100%, respectively. Preliminary safety studies (acute toxicity in mice) disclosed that 3a, 3d and 3n was well-tolerated in KM mice with LD50s of 2982.8, 3349.4 and 3126.9 mg/kg, respectively. Collectively, the data obtained in this study indicate that 3a, 3d and 3n, in particular 3n, could considered as promising candidates for the potential treatment of H. pylori caused gastritis and gastric ulcer, and hence merit further studies.

Enantioselective synthesis of arylglycine derivatives by direct C-H oxidative cross-coupling

Wei, Xiao-Hong,Wang, Gang-Wei,Yang, Shang-Dong

supporting information, p. 832 - 835 (2015/02/05)

A new method for the synthesis of chiral α-amino acid derivatives by enantioselective C-H arylation of N-aryl glycine esters with aryl boric acids in the presence of a chiral Pd(ii)-catalyst has been developed. This work successfully integrates the direct C-H oxidation with asymmetric arylation and exhibits excellent enantioselectivity. This journal is

Pharmaceutical compositions containing a 4, 5-dihydro-1, 3-thiazol-2-ylamine derivative, novel derivatives and preparation thereof

-

, (2011/05/18)

The present invention relates to pharmaceutical compositions containing, as active principle, a 4,5-dihydro-1,3-thiazol-2-ylamine derivative of formula (I): in which R represents an —alk—S—alk—Ar radical, a phenyl radical or a phenyl radical substituted w

Exploration of N-Phosphonoalkyl-, N-Phosphonoalkenyl-, and N-(Phosphonoalkyl)phenyl-Spaced α-Amino Acids as Competitive N-Methyl-D-aspartic Acid Antagonists

Bigge, Christopher F.,Johnson, Graham,Ortwine, Daniel F.,Drummond, James T.,Retz, Daniel M.,et al.

, p. 1371 - 1384 (2007/10/02)

A series of N-substituted α-amino acids containing terminal phosphonic acid groups has been synthesized as potential N-methyl-D-aspartate (NMDA) receptor antagonists.NMDA receptor affinity was determined by displacement of a known ligand (CPP) from crude rat brain synaptic membranes; an antagonists action was demonstrated by the inhibition of glutamate-induced accumulation of (45Ca2+> in cultured rat cortical neurons.Receptor affinity was significantly correlated with antagonist activity (Figure 1).Moderate affinity (IC50 = 1-2 μM) was retained for analogues (31 and 32, Table I; and 59 and 66, Table II) with reduced flexibility in their phosphonate side chains and is consistent with entropy playing a role in determining receptor affinity.Modeling studies suggest a folded conformation that brings the distal phosphonic acid group into close proximity with the α-carboxylate is required for binding.Each of the active analogues possess entropy-limiting features (double bonds, phenyl rings) in their side chains that allows the superposition of their key NH2, α-COOH, and distal PO3H2 groups with those of known competitive antagonists.Affinity decreased for analogues with α-carbon substitution, presumably because the α-substituent inhibits the folding of these structures into a bioactive conformation and occupies receptor-excluded volume.A complete description of the NMDA antagonist pharmacophore model is provided in a companion paper.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 2521-91-7